Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (366 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 12 Feb 2026 – 20 Aug 2026, limited by Kotak Nifty200 Value 30 Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Kotak Nifty200 Value 30 Index Fund | Nifty 500 |
|---|---|---|
| 12 Feb 2026 | ₹100.00 | ₹100.00 |
| 28 Feb 2026 | ₹102.24 | ₹97.95 |
| 16 Mar 2026 | ₹93.21 | ₹90.90 |
| 31 Mar 2026 | ₹89.27 | ₹86.79 |
| 16 Apr 2026 | ₹98.58 | ₹95.79 |
| 02 May 2026 | ₹98.42 | ₹95.91 |
| 18 May 2026 | ₹96.11 | ₹94.97 |
| 02 Jun 2026 | ₹97.10 | ₹95.22 |
| 18 Jun 2026 | ₹98.41 | ₹98.12 |
| 04 Jul 2026 | ₹96.21 | ₹98.52 |
| 20 Jul 2026 | ₹96.53 | ₹98.67 |
| 04 Aug 2026 | ₹96.81 | ₹100.16 |
| 20 Aug 2026 | ₹94.42 | ₹99.41 |
| Metric | Kotak Mahindra · Regular NAV ₹9.59 Very High risk Unrated | Category median Index Funds · 366 funds |
|---|---|---|
| — | +5.43% | |
| — | +8.41% | |
| — | +8.95% | |
| — | +11.28% | |
| -5.58% | +7.40% | |
| -10.15% | — | |
| — | +11.37% | |
| — | +13.00% | |
| — | +11.07% | |
| Risk | ||
| 18.18% | 13.88% | |
| — | 0.25 | |
| — | 0.35 | |
| -13.52% | -16.66% | |
| Nifty 500 | — | |
| — | +0.30% | |
| — | 1.00 | |
| — | 101.3% | |
| — | 98.8% | |
| 1.52% | 0.96% | |
| ₹28.27Cr | ₹182.17Cr | |
| None | — | |
| None | — | |
| ₹100 | — | |
| ₹2.02K | — | |
| 79% | 35% | |
| Abhishek Bisen | — | |
| 12 Feb 2026 | — | |
| 30 | — | |
| 49.0% | — | |
| 0.4% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.